Corsair Pharma Announces Appointment of George W. Mahaffey as Chief Executive Officer

Corsair Pharma Announces $23 Million Series B Financing to Advance Clinical Trials in PAH

Corsair Pharma, Inc. to Present at LifeSci Partners Annual Private Company Summer Symposium

July 8th: KOL Webinar for Pulmonary Arterial Hypertension

Corsair Pharma to Host Key Opinion Leader Meeting on Pulmonary Arterial Hypertension

Corsair & United Therapeutics Enter Strategic Collaboration to Advance Novel Treprostinil Prodrugs